Abstract
Subcutaneous Daratumumab Plus Standard Treatment Regimens in Patients with Multiple Myeloma across Lines of Therapy: Pleiades Study Update
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have